Alex Rosenberg
Alex Rosenberg is the Cofounder and CEO at Parse Biosciences, a startup that was acquired. He has expertise in biosciences and leadership.
Seattle’s UW research, Amazon alumni and military adjacency fuel startups building high-stakes, regulation-ready AI for biotech, finance and government
A Seattle high-school intern argues that strict school AI rules illuminated why AI must be disciplined in high-stakes domains, and describes how Seattle's research institutions (notably UW and the David Baker ecosystem), Amazon alumni, and military adjacency produce founders building accountable, regulation-ready AI for biotech, finance, and government.
Qiagen to Acquire Seattle’s Parse Biosciences for $225 Million in Cash Deal Closing December 2023
Seattle's Parse Biosciences, a single-cell RNA sequencing company founded in 2018, is being acquired by Netherlands-based Qiagen in a $225 million cash deal expected to close in December. Parse, which serves 3,000 customers globally and raised over $50 million in funding, will continue operating from its Seattle headquarters as a Qiagen subsidiary.
Seattle Biotech Startup Parse Biosciences Acquires Biomage to Enhance Single-Cell RNA Analysis
Seattle biotech startup Parse Biosciences has acquired Scotland-based Biomage, a single-cell RNA data analysis software company, adding about 10 employees and appointing Biomage's CEO as head of bioinformatics. This follows Parse's $50 million capital raise in December and aims to enhance single-cell sequencing analysis capabilities.
Organizations
-
Parse Biosciences Cofounder and CEO 2019–present · current
-
University of Washington Postdoctoral Researcher 2016–2019, Phd Candidate 2010–2016 · past
-
Microsoft Research Intern - MSR 2015 · past
Education
-
University of Washington Doctor of Philosophy (Ph.D.), Genetics, Synthetic Biology, Machine Learning · 2010–2016
-
University of Michigan BSE, Electrical Engineering · 2006–2010
